At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Founder operating in the Medical Device space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Gregory Winter
Scientific Founders of Bicycle Therapeutics
Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge. Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale. Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.
Follow Gregory Winter:
About Ahren Innovation Capital, Bicycle Therapeutics, MRC Laboratory of Molecular Biology, Trinity College, Dublin: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Christian Heinis
Scientific Founders of Bicycle Therapeutics
Christian Heinis is Scientific Founders at Bicycle Therapeutics.
Follow Christian Heinis:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Oliver Armitage
Co-Founder & CSO of BIOS
Oliver Armitage is Co-Founder and Chief Scientific Officer at BIOS, a leading neural engineering startup. Oliver has always had a vision that the human body could be repaired or made better through augmentative technology and how that can be used to improve people’s lives. He studied for his PhD at the University of Cambridge in Bioengineering, working in the world-renowned Nanoscience Centre. He specializes in tissue interfaces and engineering to allow technology to be fused with the body. Oliver was recently named to Forbes 30 Under 30 2018.
Follow Oliver Armitage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Giulio Ruffini
President, CTO, Co-Founder of Neuroelectrics
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders, and improves overall brain health.
Glenn Robertelli
Co-Founder & Chief Operating Officer of Admetsys
Follow Glenn Robertelli:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Mosin Badkar
Co-Founder and VP of Cardiac Design Labs
Mosin Badkar is responsible for product R and D and Algorithms. His scope includes design of new products, prototyping of design and proof of concept. His scope also includes planning and tracking of new product designs, system level and various software development activities.
Follow Mosin Badkar:
About Cardiac Design Labs: Cardiac Design Labs is into designing, developing, deploying and selling intelligent devices for medical purpose.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Nathan Rodman
CTO and Co-Founder of Perch
Nathan Rodman and Jacob Rothman founded Perch in July 2016, since which Nate has been serving as its chief technology officer.
Follow Nathan Rodman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Eoin McKinney
Chief Scientific Officer & Co-Founder of PredictImmune
Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Follow Eoin McKinney:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Kenneth Smith
Co-Founder & Chief Medical Officer of PredictImmune
Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Follow Kenneth Smith:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
M. Charles Liberman
Founder of Decibel Therapeutics
M. Charles Liberman is the Schuknecht Professor of Otology and Laryngology at the Harvard Medical School and the Director of the Eaton-Peabody Laboratories at the Massachusetts Eye and Ear, one of the largest and best-known research groups devoted to the study of hearing and deafness. The laboratory comprises 27 investigators, with research foci spanning all aspects of the auditory system from sound transmission in the middle ear, through signal transduction in the inner ear and neural processing in the central nervous system. Dr. Liberman received his B.A. in Biology from Harvard College in 1972 and his Ph.D. in Physiology from Harvard Medical School in 1976. He has been on the faculty at Harvard since 1979, has published over 160 papers on a variety of topics in auditory neuroscience and is the recipient of the Award of Merit from the Association for Research in Otolaryngology, the Carhart Award from the American Auditory Society and Bekesy Silver Medal from the Acoustical Society of America. His research interests include 1) coding of acoustic stimuli as neural responses, 2) efferent feedback control of the auditory periphery, 3) mechanisms underlying noise-induced hearing loss, 4) the signaling pathways mediating nerve survival in the inner ear and 5) application of cell- and drug-based therapies to the repair of a damaged inner ear.
Follow M. Charles Liberman:
About Decibel Therapeutics: Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Gabriel Corfas
Founder of Decibel Therapeutics
Follow Gabriel Corfas:
About Decibel Therapeutics, University of Michigan, University of Michigan Medical School: Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Pierre Leurent
Founder & CEO of Voluntis
Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.
Follow Pierre Leurent:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Oriane Chausiaux
Founder Director – CSO, Serial Entrepreneur of Heartfelt Technologies
Follow Oriane Chausiaux:
About Heartfelt Technologies: Heartfelt Technologies are developing the only home-based heart failure monitor that does not require patient interaction or compliance.
Anurag Agarwal
Founder of The Cambridge Stethoscope Company
Follow Anurag Agarwal:
About The Cambridge Stethoscope Company: The Cambridge Stethoscope Company is developing the world’s first intelligent stethoscope that is capable of automated diagnosis.
Laurence Rahme
Scientific Founder of Spero Therapeutics
Laurence RahmeLaurence Rahme, MS, PhD, is the Scientific Founder of Spero Therapeutics in Cambridge.
Follow Laurence Rahme:
About Harvard Medical School, Spero Therapeutics: Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
Sudhir Borgonha
Co-Founder and Chief Medical Officer of ten3T
Follow Sudhir Borgonha:
About ten3T: ten3T is a medical grade wearable device startup.
Danielle Zurovcik
Founder & CEO of WiCare
Danielle Zurovcik is the founder and CEO of WiCare.
Follow Danielle Zurovcik:
About WiCare: WiCare develops innovative medical devices that are clinically effective and affordable worldwide.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Christopher Loose
Co-Founder and Chief Technology Officer of Semprus BioSciences
Follow Christopher Loose:
About Semprus BioSciences: Semprus BioSciences is a venture-backed biomedical company developing medical devices implementing the Semprus technology.
David Liu
Founder of Ensemble Discovery
Follow David Liu:
About Ensemble Discovery: Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.
